Pancreatic Cancer Research

ResearcherUniversity of North Carolina at Chapel HillActive in the last 2 years

Jakob Kirkegård

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-6994-0637; OpenAlex author ID A5045254677. Sources: ClinicalTrials.gov.

Their work

Papers
27 (first author 0, last author 2)
Trials
1 (principal investigator on 1)
Grants
0
Labs led
1
Collaborators
62
Papers, trials and grants by year

2017: 1 paper · 2018: 2 papers · 2019: 6 papers · 2020: 4 papers · 2021: 1 paper · 2022: 2 papers, 1 trial · 2023: 2 papers · 2024: 5 papers · 2025: 2 papers · 2026: 2 papers

Papers 27

  1. Futility in adenosquamous pancreatic cancer. Co-author DOI 10.1186/s12957-026-04351-1↗
  2. Chemotherapy and Supportive Care Practice Patterns Among Older Adults With Metastatic Pancreatic Cancer. Co-author DOI 10.1200/op-25-00534↗
  3. Preoperative EUS-guided biopsy does not affect survival in patients with pancreatic cancer: A nationwide cohort study. Co-author DOI 10.1097/eus.0000000000000156↗
  4. Performance of Different Comorbidity Indices in Predicting Mortality in Danish Pancreatic Cancer Patients. Co-author DOI 10.2147/clep.s560098↗
  5. Beta-blocker use and survival after pancreatic cancer surgery: A nationwide population-based cohort study. Co-author DOI 10.1002/pds.5726↗
  6. Surveillance after surgery for pancreatic cancer: a global scoping review of guidelines and a nordic Survey of contemporary practice. Co-author DOI 10.1080/00365521.2024.2378948↗
  7. Effect of adjuvant chemotherapy after pancreatectomy in patients with node-negative pancreatic cancer: target trial emulation. Co-author DOI 10.1093/bjs/znad398↗
  8. Effect of surgery versus chemotherapy in pancreatic cancer patients: a target trial emulation. Co-author DOI 10.1093/jnci/djae024↗
  9. Impact on Survival of Early Versus Late Initiation of Adjuvant Chemotherapy After Pancreatic Adenocarcinoma Surgery: A Target Trial Emulation. Co-author DOI 10.1245/s10434-023-14497-x↗
  10. Impact of prior cancer diagnosis on pancreatic cancer outcomes: A Danish Nationwide, population-based Cohort study. Last author DOI 10.1016/j.canep.2023.102452↗
  11. Real-Time Identification of Pancreatic Cancer Cases Using Artificial Intelligence Developed on Danish Nationwide Registry Data. Last author DOI 10.1200/cci.23.00084↗
  12. Trends in pancreatic cancer incidence, characteristics, and outcomes in Denmark 1980-2019: A nationwide cohort study. Co-author DOI 10.1016/j.canep.2022.102230↗
  13. Disparity in use of modern combination chemotherapy associated with facility type influences survival of 2655 patients with advanced pancreatic cancer. Co-author DOI 10.1080/0284186x.2021.2012252↗
  14. Intra-observer agreements in multidisciplinary team assessments of pancreatic cancer patients. Co-author DOI 10.1002/jso.26670↗
  15. Statins and pancreatic cancer risk in patients with chronic pancreatitis: A Danish nationwide population-based cohort study. Co-author DOI 10.1002/ijc.32264↗
  16. Acute pancreatitis as an early marker of pancreatic cancer and cancer stage, treatment, and prognosis. Co-author DOI 10.1016/j.canep.2019.101647↗
  17. Predictors of underlying pancreatic cancer in patients with acute pancreatitis: a Danish nationwide cohort study. Co-author DOI 10.1016/j.hpb.2019.08.013↗
  18. Reply to Liu et al., "Study of underlying pancreatic cancer could be improved". Co-author DOI 10.1016/j.hpb.2020.05.004↗
  19. Multicentre study of multidisciplinary team assessment of pancreatic cancer resectability and treatment allocation. Co-author DOI 10.1002/bjs.11093↗
  20. Author response to: It is time for a biological definition of locally advanced pancreatic cancer. Co-author DOI 10.1002/bjs.11250↗
  21. Author's Reply to: "Design flaws in statins and pancreatic cancer research" (IJC-19-0941). Co-author DOI 10.1002/ijc.32349↗
  22. Waiting time to surgery and pancreatic cancer survival: A nationwide population-based cohort study. Co-author DOI 10.1016/j.ejso.2019.05.029↗
  23. Antihypertensive drugs and pancreatic cancer risk in patients with chronic pancreatitis: a Danish nationwide population-based cohort study. Co-author DOI 10.1038/s41416-019-0562-y↗
  24. Comment on "Surgery Improves Survival After Neoadjuvant Therapy for Borderline and Locally Advanced Pancreatic Cancer". Co-author DOI 10.1097/sla.0000000000003422↗
  25. Acute Pancreatitis and Pancreatic Cancer Risk: A Nationwide Matched-Cohort Study in Denmark. Co-author DOI 10.1053/j.gastro.2018.02.011↗
  26. Urban versus rural residency and pancreatic cancer survival: A Danish nationwide population-based cohort study. Co-author DOI 10.1371/journal.pone.0202486↗
  27. Chronic Pancreatitis and Pancreatic Cancer Risk: A Systematic Review and Meta-analysis. Co-author DOI 10.1038/ajg.2017.218↗

Trials 1

  1. Incremental Value of Magnetic Resonance Imaging in Selection of Pancreatic Cancer Patients for Surgery Principal investigator NCT05428358↗

Closest collaborators

The 25 strongest of 62 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Frank Viborg Mortensen · 24 shared papers, 2017–2025 · strength 4.63
  2. Deirdre P Cronin-Fenton · 11 shared papers, 2017–2024 · strength 1.85
  3. Uffe Heide‐Jørgensen · 6 shared papers, 2018–2025 · strength 1.13
  4. Claus Wilki Fristrup · 7 shared papers, 2018–2025 · strength 1.03
  5. Morten Bækbo Ladekarl · 5 shared papers, 2018–2024 · strength 0.98
  6. Charles E. Gaber · 3 shared papers, 2020–2026 · strength 0.69
  7. Jennifer Leigh Lund · 4 shared papers, 2019–2024 · strength 0.66
  8. Carsten Palnæs Hansen · 4 shared papers, 2018–2025 · strength 0.63
  9. Michael Bau Mortensen · 4 shared papers, 2019–2025 · strength 0.55
  10. Anders Bo Bojesen · 2 shared papers, 2022–2023 · strength 0.53
  11. MD, DMSc Frank Mortensen · 1 shared trial, 2022 · strength 0.49
  12. Bodil Andersson · 2 shared papers, 2024–2026 · strength 0.34
  13. Bergþór Björnsson · 2 shared papers, 2024–2026 · strength 0.34
  14. Svein Olav Bratlie · 3 shared papers, 2019–2024 · strength 0.34
  15. Ryan David Nipp · 1 shared paper, 2026 · strength 0.33
  16. Nickolai Malte Kristensen · 1 shared paper, 2023 · strength 0.31
  17. Peter Vilmann · 1 shared paper, 2025 · strength 0.26
  18. Mogens Tornby Stender · 1 shared paper, 2025 · strength 0.26
  19. Bojan Kovacevic · 1 shared paper, 2025 · strength 0.26
  20. Sönke Detlefsen · 1 shared paper, 2025 · strength 0.26
  21. Cristina Vallejo Bernad · 1 shared paper, 2026 · strength 0.18
  22. Julie Navez · 1 shared paper, 2026 · strength 0.18
  23. Santiago Sánchez-Cabús · 1 shared paper, 2026 · strength 0.18
  24. Sebastian Manuel Staubli · 1 shared paper, 2026 · strength 0.18
  25. Dimitrios E. Giakoustidis · 1 shared paper, 2026 · strength 0.18

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.